Kite To Acquire Tmunity Therapeutics To Pursue Next Generation Car T-Cell Therapy Advancements In Cancer
Kite To Acquire Tmunity Therapeutics To Pursue Next Generation Car T-Cell Therapy Advancements In Cancer
12/20/22, 1:04 PM
Location
philadelphiaIndustry
therapeutics
biotechnology
manufacturing
therapeutics
manufacturing
biotechnology
Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a strategic research and licensing agreement with the University of Pennsylvania (Penn).
Company Info
Company info
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.